Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...910111213141516171819...858859»
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Journal, Adverse events:  KRAS-G12 inhibitors in lung cancer therapy: unveiling the toxicity profile through a pharmacovigilance study. (Pubmed Central) -  Nov 21, 2024   
    In this Phase 2 study we will investigate the combination of chemotherapy given concurrently with immunotherapy in attempt to improve response rates and prolong survival for relapsed or refractory pediatric patients with B-ALL. Although most adverse effects are reversible, vigilance is warranted particularly for nephrotoxicity and hepatotoxicity during the administration of KRAS G12C inhibitors.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal, CAR T-Cell Therapy, PD(L)-1 Biomarker, IO biomarker:  Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research. (Pubmed Central) -  Nov 21, 2024   
    Keyword clustering revealed six core themes: "Expression," "Chimeric Antigen Receptor," "Tumor Microenvironment," "Blinatumomab," "Multiple Myeloma," and "Cytokine Release Syndrome." In the process of researching the timeline chart of keywords and references, "Large B-cell lymphoma" was located on the right side of the timeline...We found that in terms of related diseases, "large B-cell lymphoma" and "cytokine release syndrome" are still difficult problems in the future. In the study of therapeutic methods, "BCMA," "PD-1," "chimeric antigen," and "antibody drug conjugate" deserve more attention from researchers in the future.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment change, Trial completion date, Trial primary completion date:  Palbociclib and Pembrolizumab in Central Nervous System Metastases (clinicaltrials.gov) -  Nov 21, 2024   
    P2,  N=45, Recruiting, 
    These findings regarding long-term persistence in treatment may be useful for therapeutic decision-making based on real-life cohort results. N=30 --> 45 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab-associated symptomatic hypophosphatemia in normal kidney function: two case reports. (Pubmed Central) -  Nov 20, 2024   
    As prescription rates of denosumab therapy increase, attention should be paid to the risk of developing hypophosphatemia: the risk of such complication may be lower by early and regular monitoring of Ca, Pi, and PTH, as well as early supplementation of phosphate and/or vitamin D as needed. Whenever a patient receiving denosumab therapy complains otherwise unexplained fatigue, exercise intolerance, muscle pain, cramping, and paresthesias, we suggest hypophosphatemia as a potential complication to be ruled out.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  One versus 2 (Pubmed Central) -  Nov 20, 2024   
    P4
    In addition, the risk of MACE was comparable between the two drugs. With the limitations of our small sample size, these data suggest that both 1 and 2
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Journal:  Linking Downbeat Nystagmus and Aquaporin-4-Positive Neuromyelitis Optica: A Closer Look at Their Hidden Relationship. (Pubmed Central) -  Nov 20, 2024   
    NMO may be associated with antibodies selective for aquaporin-4 (AQP4), a water channel located within the optic nerves and spinal cord.AQP4 is distributed in the periventricular region, corpus callosum, magnocellular nuclei of the hypothalamus, and brain stem.Downbeat nystagmus (DBN) is associated with structural, metabolic, and autoimmune disorders, but is rarely reported in NMO.We treated a 33-year-old female with known AQP4-positive NMO who presented with new-onset DBN. We review the literature and discuss possible mechanisms and lesion locations hypothetically responsible for the symptoms and signs.
  • ||||||||||  Review, Journal:  Stable Angina Pectoris: A Review of Pathophysiology, Diagnosis, and Its Management. (Pubmed Central) -  Nov 20, 2024   
    Antianginal treatment options are categorized as first line (calcium channel blockers (CCBs), ?-blockers, and short-acting nitrates) and second line (ivabradine, nicorandil, ranolazine, and trimetazidine) drugs. This review discusses different CCBs (dihydropyridines (DHPs) or nondihydropyridines) for the management of angina pectoris.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Enrollment change:  G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov) -  Nov 20, 2024   
    P2,  N=60, Not yet recruiting, 
    Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile. N=40 --> 60
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion, Surgery, Bariatric surgery:  Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery (clinicaltrials.gov) -  Nov 20, 2024   
    P4,  N=36, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma, Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Review, Journal:  Neuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review. (Pubmed Central) -  Nov 19, 2024   
    Simultaneously, sequential disease-modifying therapy was initiated, starting with long-term oral administration of mycophenolate mofetil, followed by cyclophosphamide, telitacicept, and Inebilizumab...Early and comprehensive evaluation of autoimmune diseases is crucial in patients with NMOSD presenting with u-LETM as the initial symptom. Prompt treatment initiation, followed by disease-modifying therapy, is essential for improving patient prognosis.
  • ||||||||||  Journal:  Drugs for asthma. (Pubmed Central) -  Nov 19, 2024   
    Atogepant demonstrated a favorable benefit-risk profile, with NNT and NNH values comparable (not statistically significant) with those of CGRP mAbs across all analyses. No abstract available
  • ||||||||||  Evrenzo (roxadustat) / FibroGen
    Trial completion date, Trial primary completion date:  FOXTROT: The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (clinicaltrials.gov) -  Nov 19, 2024   
    P2,  N=30, Not yet recruiting, 
    No abstract available Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
  • ||||||||||  zetomipzomib (KZR-616) / Kezar
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE) (clinicaltrials.gov) -  Nov 19, 2024   
    P2,  N=84, Terminated, 
    Not yet recruiting --> Recruiting N=279 --> 84 | Trial completion date: Jul 2026 --> Nov 2024 | Suspended --> Terminated | Trial primary completion date: May 2026 --> Nov 2024; Sponsor Decision.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Review, Journal:  Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs. (Pubmed Central) -  Nov 18, 2024   
    Based on positive clinical trial results, TZP appears to offer a promising, safe, and effective treatment approach. This narrative review examines the evidence for treating severe asthma with TZP, analyses clinical trial findings, and provides clinicians with practical insights into identifying patients who may respond best to this novel biologic therapy.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy. (Pubmed Central) -  Nov 18, 2024   
    This narrative review examines the evidence for treating severe asthma with TZP, analyses clinical trial findings, and provides clinicians with practical insights into identifying patients who may respond best to this novel biologic therapy. Treatment with ROMO significantly increased lumbar spine BMD in GC-treated patients, suggesting that ROMO is effective for GIOP.
  • ||||||||||  ivabradine / Generic mfg.
    Review, Journal:  Postural orthostatic tachycardia syndrome after COVID-19 vaccination: A systematic review. (Pubmed Central) -  Nov 18, 2024   
    The risk of POTS following COVID-19 vaccination is lower than that observed post-SARS-CoV-2 infection; however, existing studies are limited by small sample sizes and methodological variability. Further research is needed to clarify the incidence, mechanisms, and long-term outcomes of vaccine-related POTS to inform effective clinical management strategies.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  Pharmacological management of heart failure: a patient-centered approach. (Pubmed Central) -  Nov 18, 2024   
    In this context, a patient-centered approach that considers comorbidities and specific clinical scenarios when dosing HF medication is essential. Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment closed:  OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) -  Nov 18, 2024   
    P3,  N=284, Active, not recruiting, 
    Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials. Recruiting --> Active, not recruiting
  • ||||||||||  Hulio (adalimumab-fkjp) / Fujifilm Kyowa Kirin Biologics, Biocon, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hyrimoz (adalimumab-adaz) / Sandoz
    Enrollment closed, Trial completion date, Trial primary completion date:  Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE (clinicaltrials.gov) -  Nov 18, 2024   
    P=N/A,  N=46, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2024 --> Nov 2024